José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Complejo Asistencial Universitario de Burgos
Burgos, EspañaPublikationen in Zusammenarbeit mit Forschern von Complejo Asistencial Universitario de Burgos (29)
2024
-
Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)
Scientific Reports
-
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
Leukemia
-
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
HemaSphere
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
-
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
Leukemia
-
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
American Journal of Hematology
2023
-
Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia
HemaSphere, Vol. 7, Núm. 8, pp. E936
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
2022
-
Breakthrough infections in MPN-COVID vaccinated patients
Blood Cancer Journal
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
American Journal of Hematology
-
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239
-
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
-
Second versus first wave of COVID-19 in patients with MPN
Leukemia
2021
-
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Blood Cancer Journal, Vol. 11, Núm. 2
-
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia
British Journal of Haematology, Vol. 192, Núm. 6, pp. 988-996
-
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
Leukemia, Vol. 35, Núm. 2, pp. 485-493
-
Long-term follow-up of recovered MPN patients with COVID-19
Blood Cancer Journal
-
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Blood Cancer Journal